Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...

Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...

Mike Davis previously worked as clinical team leader at the FDA’s Division of Psychiatry before serving as chief medical ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

The newly appointed members of the CDC’s influential vaccine committee meet Wednesday and Thursday under an unusually rapid ...